



BioSig[™]
technologies

BIOSIG TECHNOLOGIES, INC.

OFFICIAL COMPANY NEWSLETTER

Issue 6 | September 2021

WHAT'S INSIDE:

ABOUT US • P.2

ABOUT THE PURE EP[™] SYSTEM • P.2

A MESASAGE FROM OUR LEADERSHIP • P.2

NEW INSTALLATION IN BOSTON • P.3

BIOSIG, PLEXUS CORPORATE ENTER NEW PARTNERSHIP • P.3

BIOSIG APPOINTS JAMES J. BARRY TO BOARD OF DIRECTORS • P.4

THE MARK E. JOSEPHSON VIRTUAL SYMPOSIUM • P.4

BIOSIG IN THE NEWS • P.5

#AFIBAWARENESS MONTH • P.6

JOIN US FOR: BIOELECTRONIC MEDICINE TALKS, PART 2 • P.6

BIOSIG'S 2022 INTERNSHIP! • P.7

KUDOS... • P.7

We are Sending A Clear Signal Across Cardiac care

BioSig is the bioelectronic intelligence company on a mission to preserve the unaltered value of heart signals, gather and provide the real data physicians need to better control procedures today, and predict better treatment pathways for tomorrow. We are showing the way to help improve outcomes for every patient.

As innovators in the electrophysiology (EP) space, our main focus is addressing the unmet needs of the field. The PURE EP™ System is designed to improve the \$4 billion EP market through a powerful combination of hardware and software that makes better decision-making possible.

Better *Intelligence*, Better *Outcomes*

The PURE EP™ System offers a novel way to acquire and process cardiac signals. These are essential diagnostic signals that deliver high clinical value in all types of cardiac ablations.

No other systems or technologies preserve the purity of signals physicians need to deliver better outcomes. PURE EP™ was designed to improve clinical decision making by providing the full cardiac picture. When it comes to operating on a patient's heart, there is no room for uncertainty.



To date, over **66 physicians** have completed more than **1,500 patient cases** with the PURE EP™ System across **thirteen clinical sites** that include Mayo Clinic, The University of Pennsylvania Hospital, Weill Cornell Medical Center, and more.



A MESSAGE FROM OUR LEADERSHIP

*By Ken Londoner, CEO & Co-Founder,
BioSig Technologies, Inc.*


The Month of September has been one of significant growth for our company. We recently announced that we have officially moved and settled into our new headquarters in Westport, Connecticut. This growth and expansion extended to almost every facet of our company, including the appointment of medical device industry leader, Dr. James J. Barry to our company's Board of Directors, the announcement of a new partnership with global manufacturing leader, Plexus Corporate, and the expansion of our clinical footprint in one of our nation's largest MedTech hubs, Boston, Massachusetts.

But, amidst all the excitement, it is important not to forget that September also marks National Atrial Fibrillation Awareness Month, a critical time to acknowledge the growing prevalence of a devastating heart condition. In the U.S. alone, over 3 million people are currently suffering from Afib, a heart rhythm abnormality that carries a 35% lifetime risk for those age 55 and older.

BioSig's core mission is to help improve the lives of those suffering from Afib and other types of cardiac arrhythmia. We hope that in doing so we can in turn help decrease the prevalence of this growing health epidemic. As I contemplate and celebrate the milestones that BioSig achieved this past month, I am equally proud of the critical cause they contribute to.

EXPANDING OUR PRESENCE IN THE BOSTON MARKET

This past month, we announced a new installation agreement for the PURE EP™ System at St. Elizabeth's Medical Center in Boston, MA. The evaluation program under the leadership of Michael Orlov, M.D., aims to assess the PURE EP™ System during a series of physiologic pacing procedures. Physiologic pacing is an emerging pacing technique designed to activate the normal cardiac conduction system and synchronize contraction of the ventricles. This approach to pacing the heart has demonstrated improved clinical and hemodynamic benefits beyond standard pacing techniques.



“

"It is very exciting to embark on this new clinical journey. Our ultimate goal is to empower more physicians that want to make better clinical decisions for their patients... This is why it is very important to continue partnering with innovative hospitals that are pushing the boundaries with novel techniques that have the potential to transform arrhythmia care."

*~Natasha Drapeau, Executive Vice President
BioSig Technologies, Inc.,
Interview with Proactive, September 2021*

[Watch Natasha's Proactive Interview](#)

BIOSIG SELECTS PLEXUS AS NEW NEW MANUFACTURING PARTNER



We are thrilled to announce that we have entered a manufacturing and professional services agreement with Plexus Corp. (Nasdaq:PLXS), a global leader in complex product design, manufacturing, supply chain and aftermarket services.

[Read the full announcement](#)

Plexus counts healthcare and life sciences as one of its largest market sectors representing nearly 40% of annual revenue. Their engineering and manufacturing capabilities and outstanding expertise in building complex medical devices make Plexus a foundational cornerstone to support BioSig's growth objectives now and well into the future. We believe that the post-pandemic recovery in elective procedures will further drive our installation footprint and are confident that Plexus' first-class operational infrastructure will ensure a quality supply of the PURE EP™ systems to meet growing market needs.

“

The PURE EP™ System is an innovative, breakthrough device that will greatly improve the healthcare opportunities for physicians and patients alike... We look forward to furthering our vision of helping create the products that build a better world."

~Michael Tendick, VP of Healthcare and Life Sciences Market Sector, Plexus Corp.

BIOSIG APPOINTS MEDICAL DEVICE INDUSTRY LEADER TO ITS BOARD OF DIRECTORS

A WARM WELCOME TO DR. JAMES J. BARRY, PH.D.

At the end of September, we proudly announced that former President and CEO at InspireMD and Sr. Vice President of Corporate Technology at Boston Scientific, has joined BioSig's Board of Directors.

Dr. Barry spent the majority of his career at Boston Scientific (NYSE: BSX) with increasing roles of responsibility culminating as Sr. Vice President of Corporate Technology. While at Boston Scientific, Dr. Barry led the development and launch of the TAXUS drug-eluting coronary stent that achieved annual sales exceeding \$3 billion. Click the link below to learn more about Dr. Barry's impressive career.

[Learn more about Dr. Barry.](#)

“

I have always viewed the electrophysiology field as a tremendous opportunity given the burden heart rhythm disorders have on the healthcare system. It is a space that can benefit greatly from innovation, and I am impressed with the PURE EP system which appears to be a meaningful advance in signal detection and should have a positive impact on procedure time and cost.”

~ James J. Barry, PhD., Director, BioSig Technologies, Inc.

SEPTEMBER CONFERENCES

THE MARK E. JOSEPHSON TWENTY-EIGHT ANNUAL STATE-OF-THE-ART ARRHYTHMIA VIRTUAL SYMPOSIUM


The world-renown Mark E. Josephson Symposium, held virtually on September 11, 2021, was designed to provide electrophysiologists, cardiologists, internists, and associated professionals with state-of-the art information on invasive and non-invasive electrocardiographic and electrophysiologic tools used in the diagnosis, evaluation, and treatment of cardiac rhythm disorders. The symposium pays tribute to the scientific and clinical legacy of Dr. Mark E. Josephson, an American cardiologist and writer known as one of the American pioneers of cardiac electrophysiology.

[Learn more about The Mark E. Josephson Symposium](#)


“

Dr. Josephson's intellectual integrity and his unwavering dedication to advancing cardiac electrophysiology was the driving force behind my decision to focus on basic science during the development of our flagship technology, the PURE EP.

~ Ken Londoner, CEO & Co-founder, BioSig Technologies, Inc.



BIOSIG'S CEO, KEN LONDONER FEATURED IN MEDICAL DEVICE NEWS MAGAZINE



In the article, Mr. Londoner sheds light on Atrial Fibrillation, a highly prevalent heart condition that affects millions.

BioSig developed the PURE EP™ System to address unmet needs in electrophysiology, a field of healthcare that has been hungry for innovation for nearly two decades. PURE EP™ functions much like a professional translator of the heart, capable of revealing the full range of cardiac signals with precise, unaltered clarity so that physicians can make clinical decisions with more confidence and assurance.

“

PURE EP is the puzzle piece that, finally, completes the entire cardiac picture. As physicians continue to discover its immense value, so too do they continue to discover the small, fractionated, erratic electrical signal causing the arrhythmia.

~ Ken Londoner, CEO & Co-founder, BioSig Technologies, Inc.

[Read the Article](#)

BENZINGA EXCLUSIVE INTERVIEW WITH BIOSIG'S EXECUTIVE VICE PRESIDENT

“

The national Afib costs are estimated to range from \$6 to \$26 billion. We feel it is our duty to help improve this outlook by partnering with more physicians that are developing novel techniques that aim to relieve their patients and the broader communities from the burdens associated with arrhythmias.

~ Natasha Drapeau, Executive Vice President,
BioSig Technologies, Inc.

It's been a busy month for BioSig's Executive Vice President. Natasha Drapeau also represented the company in a virtual interview with Michael Murray from Benzinga where she discusses BioSig's latest installation at St. Elizabeth's, the significance of the key strategic region of the Northeast, and future opportunities for the company.



BENZINGA



[Watch the Interview](#)

#AFIBMONTH

National Atrial Fibrillation Awareness Month

September marks National Atrial Fibrillation Month, a critical time to raise awareness about one of the most common, yet underestimated heart conditions. In honor of this important public health awareness month, I encourage everyone to make a donation to the American Heart Association, a leading resource for cardiovascular disease.

As an additional resource, check out our #AfibMonth, CEO Blog series highlighting the most important facts, initiatives, and perspectives from patients and providers about a highly common heart problem that is far too easy to miss.

3M+

known Afib cases in the US

750,000

Hospitalizations a year.

35%+

Lifetime risk for those 55+ years old.

\$26B

Annual healthcare spend.



**Read our Afib Month
CEO Blog Series**



**Donate to the American
Heart Association**



ALLIANCE for ADVANCING
BIOELECTRONIC MEDICINE

BIOELECTRONIC MEDICINE TALKS

The Alliance for Advancing
Bioelectronic Medicine presents...

BIOELECTRONIC MEDICINE TALKS

PART 2: EMERGING DIRECTIONS IN BIOELECTRONIC MEDICINE

Please join the Alliance for Advancing Bioelectronic Medicine for Part 2 of our webinar series, Bioelectronic Medicine Talks!

Featuring esteemed panelists that will discuss the bold research advances and emerging technologies that aim to expand bioelectronic medicine's potential to help more patients.

Wednesday October 13

17:00 - 18:00 PM CET

11:00 AM - 12:00 PM ET

Click Here to Register



Emil Hewage
CEO, BiosHealth



Jörn Rickert
CEO, CorTec



D.A. Wallach,
Co-Founder,
Time BioVentures

BIOSIG'S 2022 INTERNSHIP

DREAM. LEARN. GROW.

*Join an empowering environment
to launch your career.*

BioSig has offered robust internship programs since 2016. As a public company with cutting-edge medical technology, there are a wealth of opportunities available to undergrads. As a BioSig intern, you will directly observe the critical intersection between science and business, all of which will enable you to better plan for your future careers or post-graduate studies.

We encourage applications from students majoring in economics, political science, international affairs, marketing, electrical/biomedical engineering, biology, chemistry, and neuroscience. Please stay tuned for applications to open on Handshake, LinkedIn, or wherever your career center posts their internships.

“

My internship at BioSig Technologies has been an invaluable experience. With the ability to work directly with the C-suite level executives and opportunities to meet face to face with potential investors, I feel like I have had the opportunity to further advance my professional career.

~Connor Thatcher, Lafayette College '21

Since graduating from Lafayette College in 2021, Connor Thatcher has been working as a Sales Analyst at MarketAxess in NY, NY.



Meet our 2021 Summer Interns!

GET IN TOUCH

Graham Bonnell, Communications gbonnell@biosigtech.com

Chardon Brooks, Communications: cbrooks@biosigtech.com



KUDOS.

This month, we would like to extend a special thank you to our Executive Vice President, Natasha Drapeau, whose invaluable leadership reaches every area of our organization.

As both a driving force and key spokesperson for BioSig's September milestones, we would like to thank Natasha for all of her hard work this past month, and over the past five years.



Showing the Way to Better.